Acadia Pharmaceuticals Inc. ACAD
As ofNov 20, 2026, 11:15 AM EST
- YTD
- -33.85%
- 1 year
- -22.84%
5D -1.30 (-6.87%)
- Market cap
- 3.06B
- Revenue (ttm)
- 1.20B
- Profit margin
- 30.13%
- EPS (ttm)
- 2.12
- Shares out
- 172.83M
- P/E ratio
- 8.34
- Forward P/E
- 16.19
- YTD return
- -33.85%
- 1-year return
- -22.84%
- 50-day average
- 21.22
- Volume
- 442.46K
- Avg volume
- 2.17M
- Open
- 17.47
- Previous close
- 17.59
- Day's range
- 17.42 – 17.79
- 52-week range
- 15.86 – 30.96
- Beta
- 0.89
- Analysts
- Buy
- Price target
- 30.21 (+71.0%)
- Earnings date
- Feb 24, 2027
Key statistics
- 200-day average
- 23.23
- Enterprise value
- 2.18B
- PEG ratio
- 50.86
- Price / sales
- 2.53
- Price / book
- 2.19
- Revenue growth
- 22.80%
- Free cash flow
- 46.27M
- Total cash
- 976.45M
- Total debt
- 71.85M
- Return on equity
- 31.43%
- Short % of float
- 7.59%
Fundamental scorecard
15 of 25 checks passed on ACAD’s reported financials
15of 25 checks passed
- Value 3 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 16.00
- Target (mean)
- 30.21
- Target (high)
- 38.00
- Strong buy4
- Buy10
- Hold5
- Sell1
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.26298.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.28 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.1992 | 0.31 | +0.11 | +55.62% |
| Aug 4, 2026 | Jun 30, 2026 | 0.06815 | 0.18 | +0.11 | +164.12% |
| May 6, 2026 | Mar 31, 2026 | 0.04 | 0.02 | -0.02 | -50.00% |
| Feb 25, 2026 | Dec 31, 2025 | 0.137 | 1.60 | +1.46 | +1,067.88% |
| Nov 5, 2025 | Sep 30, 2025 | 0.14 | 0.42 | +0.28 | +200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 19, 2026 | Needham | reit | Buy | Buy |
| Oct 13, 2026 | UBS | down | Buy | Neutral |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 25, 2026 | Deutsche Bank | main | Buy | Buy |
About Acadia Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acadia.com
News
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge Oppenheimer Maintains Perform on Acadia Pharmaceuticals, Lowers Price Target to $21
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript Acadia Pharma Presents Additional Data From Phase 2 RADIANT Trial Evaluating Remlifanserin For Treatment Of Hallucinations And Delusions Associated With ADP, At 2026 CTAD Conference
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan Morgan Stanley Maintains Equal-Weight on Acadia Pharmaceuticals, Lowers Price Target to $24
12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on ACAD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS CATHERINE OWEN | Chief Executive Officer | Sale | Mar 24, 2026 | 14,803 |
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 28, 2026 | 0 |
| BAKER BROTHERS LIFE SCIENCES L P | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | May 28, 2025 | 0 |
| BREGE LAURA A | Director | Conversion of Exercise of derivative security | May 28, 2026 | 23,202 |
| GAROFALO ELIZABETH AMY M.D. | Director | Conversion of Exercise of derivative security | May 28, 2026 | 33,489 |
| HARRIGAN EDMUND P. M.D. | Director | Conversion of Exercise of derivative security | May 28, 2026 | 43,148 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 24.83% | 42,912,904 | 754.41M | Sep 29, 2026 |
| Blackrock Inc. | 13.28% | 22,947,481 | 403.42M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.47% | 9,457,124 | 166.26M | Sep 29, 2026 |
| State Street Corporation | 4.43% | 7,650,889 | 134.50M | Sep 29, 2026 |
| RTW Investments LP | 4.13% | 7,144,524 | 125.60M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.35% | 5,790,801 | 101.80M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 4.45% | 7,694,693 | 135.27M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.36% | 4,074,465 | 71.63M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.93% | 3,329,826 | 58.54M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.71% | 2,949,287 | 51.85M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.43% | 2,472,502 | 43.47M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.98% | 1,699,377 | 29.88M | Jun 29, 2026 |
